Literature DB >> 29032195

Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.

Seth R Flaxman1, Rupert R A Bourne2, Serge Resnikoff3, Peter Ackland4, Tasanee Braithwaite5, Maria V Cicinelli6, Aditi Das7, Jost B Jonas8, Jill Keeffe9, John H Kempen10, Janet Leasher11, Hans Limburg12, Kovin Naidoo13, Konrad Pesudovs14, Alex Silvester15, Gretchen A Stevens16, Nina Tahhan3, Tien Y Wong17, Hugh R Taylor18.   

Abstract

BACKGROUND: Contemporary data for causes of vision impairment and blindness form an important basis of recommendations in public health policies. Refreshment of the Global Vision Database with recently published data sources permitted modelling of cause of vision loss data from 1990 to 2015, further disaggregation by cause, and forecasts to 2020.
METHODS: In this systematic review and meta-analysis, we analysed published and unpublished population-based data for the causes of vision impairment and blindness from 1980 to 2014. We identified population-based studies published before July 8, 2014, by searching online databases with no language restrictions (MEDLINE from Jan 1, 1946, and Embase from Jan 1, 1974, and the WHO Library Database). We fitted a series of regression models to estimate the proportion of moderate or severe vision impairment (defined as presenting visual acuity of <6/18 but ≥3/60 in the better eye) and blindness (presenting visual acuity of <3/60 in the better eye) by cause, age, region, and year.
FINDINGS: We identified 288 studies of 3 983 541 participants contributing data from 98 countries. Among the global population with moderate or severe vision impairment in 2015 (216·6 million [80% uncertainty interval 98·5 million to 359·1 million]), the leading causes were uncorrected refractive error (116·3 million [49·4 million to 202·1 million]), cataract (52·6 million [18·2 million to 109·6 million]), age-related macular degeneration (8·4 million [0·9 million to 29·5 million]), glaucoma (4·0 million [0·6 million to 13·3 million]), and diabetic retinopathy (2·6 million [0·2 million to 9·9 million]). Among the global population who were blind in 2015 (36·0 million [12·9 million to 65·4 million]), the leading causes were cataract (12·6 million [3·4 million to 28·7 million]), uncorrected refractive error (7·4 million [2·4 million to 14·8 million]), and glaucoma (2·9 million [0·4 million to 9·9 million]). By 2020, among the global population with moderate or severe vision impairment (237·1 million [101·5 million to 399·0 million]), the number of people affected by uncorrected refractive error is anticipated to rise to 127·7 million (51·0 million to 225·3 million), by cataract to 57·1 million (17·9 million to 124·1 million), by age-related macular degeneration to 8·8 million (0·8 million to 32·1 million), by glaucoma to 4·5 million (0·5 million to 15·4 million), and by diabetic retinopathy to 3·2 million (0·2 million to 12·9 million). By 2020, among the global population who are blind (38·5 million [13·2 million to 70·9 million]), the number of patients blind because of cataract is anticipated to rise to 13·4 million (3·3 million to 31·6 million), because of uncorrected refractive error to 8·0 million (2·5 million to 16·3 million), and because of glaucoma to 3·2 million (0·4 million to 11·0 million). Cataract and uncorrected refractive error combined contributed to 55% of blindness and 77% of vision impairment in adults aged 50 years and older in 2015. World regions varied markedly in the causes of blindness and vision impairment in this age group, with a low prevalence of cataract (<22% for blindness and 14·1-15·9% for vision impairment) and a high prevalence of age-related macular degeneration (>14% of blindness) as causes in the high-income subregions. Blindness and vision impairment at all ages in 2015 due to diabetic retinopathy (odds ratio 2·52 [1·48-3·73]) and cataract (1·21 [1·17-1·25]) were more common among women than among men, whereas blindness and vision impairment due to glaucoma (0·71 [0·57-0·86]) and corneal opacity (0·54 [0·43-0·66]) were more common among men than among women, with no sex difference related to age-related macular degeneration (0·91 [0·70-1·14]).
INTERPRETATION: The number of people affected by the common causes of vision loss has increased substantially as the population increases and ages. Preventable vision loss due to cataract (reversible with surgery) and refractive error (reversible with spectacle correction) continue to cause most cases of blindness and moderate or severe vision impairment in adults aged 50 years and older. A large scale-up of eye care provision to cope with the increasing numbers is needed to address avoidable vision loss. FUNDING: Brien Holden Vision Institute.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29032195     DOI: 10.1016/S2214-109X(17)30393-5

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  638 in total

Review 1.  Recent advances in intraocular sustained-release drug delivery devices.

Authors:  Yiqi Cao; Karen E Samy; Daniel A Bernards; Tejal A Desai
Journal:  Drug Discov Today       Date:  2019-06-04       Impact factor: 7.851

2.  The inverse-research law of eye health.

Authors:  John C Buchan; William H Dean; Jacqueline Ramke; Matthew J Burton
Journal:  Eye (Lond)       Date:  2019-07-11       Impact factor: 3.775

3.  Comparing the efficacy of trabeculectomy and diode laser cyclophotocoagulation in primary open-angle glaucoma.

Authors:  Somar Hasan; Theresa Theilig; Jan Darius Unterlauft
Journal:  Int Ophthalmol       Date:  2019-03-04       Impact factor: 2.031

Review 4.  Applications of augmented reality in ophthalmology [Invited].

Authors:  Güneş Aydındoğan; Koray Kavaklı; Afsun Şahin; Pablo Artal; Hakan Ürey
Journal:  Biomed Opt Express       Date:  2020-12-21       Impact factor: 3.732

5.  Seeing other perspectives: evaluating the use of virtual and augmented reality to simulate visual impairments (OpenVisSim).

Authors:  Pete R Jones; Tamás Somoskeöy; Hugo Chow-Wing-Bom; David P Crabb
Journal:  NPJ Digit Med       Date:  2020-03-10

6.  High-density lipoproteins are a potential therapeutic target for age-related macular degeneration.

Authors:  Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

7.  Bioavailability and spatial distribution of fatty acids in the rat retina after dietary omega-3 supplementation.

Authors:  Elisa Vidal; Bokkyoo Jun; William C Gordon; Marie-Annick Maire; Lucy Martine; Stéphane Grégoire; Spiro Khoury; Stephanie Cabaret; Olivier Berdeaux; Niyazi Acar; Lionel Bretillon; Nicolas G Bazan
Journal:  J Lipid Res       Date:  2020-10-30       Impact factor: 5.922

8.  Functional retinal outcomes in patients with prediabetes and type 2 diabetes.

Authors:  Nicole Karson; Jennyffer Smith; Morgan Jones; Ananya Datta; Kathryn Richdale; Wendy W Harrison
Journal:  Ophthalmic Physiol Opt       Date:  2020-09-21       Impact factor: 3.117

9.  Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration.

Authors:  Tomoko Sawada; Tsutomu Yasukawa; Hiroko Imaizumi; Hisashi Matsubara; Kazuhiro Kimura; Hiroto Terasaki; Hiroto Ishikawa; Tomoya Murakami; Masaru Takeuchi; Yoshinori Mitamura; Mariko Yamashita; Yoshihiro Takamura; Toshinori Murata; Jiro Kogo; Masahito Ohji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-17       Impact factor: 3.117

Review 10.  Interventions to improve access to cataract surgical services and their impact on equity in low- and middle-income countries.

Authors:  Jacqueline Ramke; Jennifer Petkovic; Vivian Welch; Ilse Blignault; Clare Gilbert; Karl Blanchet; Robin Christensen; Anthony B Zwi; Peter Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2017-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.